Abstract:Gastric cancer (GC) remains one of the most common digestive cancers worldwide; however, most patients present at an advanced stage at initial diagnosis. Zic1 is a novel candidate tumor suppressor gene that is epigenetically silenced in GC. In this study, we investigated Zic1 promoter methylation in plasma DNA as a novel molecular marker for the early diagnosis and monitoring of GC. Methylation-specific polymerase chain reaction (MSP) assay was performed to detect Zic1 promoter methylation in plasma DNA from 20 healthy subjects, 50 gastric intraepithelial neoplasia patients, and 104 GC patients. The Zic1 promoter methylation rate in the plasma samples from the healthy control group was 0%, but it reached 54.0% in the intraepithelial neoplasia group and 60.6% in the GC group. The latter two values were significantly higher than that found in the healthy control group (p < 0.05), with a 100% specificity for intraepithelial neoplasia and GC diagnosis. The positive predictive value of plasma Zic1 promoter methylation for the diagnosis of intraepithelial neoplasia and GC was 100%. Methylation status in the GC group was not significantly associated with tumor size, tumor differentiation, lymph node metastasis, TNM staging, or tumor invasion (p > 0.05). Assessment of the significance of detection of the carcino-embryonic antigen (CEA) level and Zic1 promoter methylation rate for GC diagnosis revealed that the sensitivity of Zic1 promoter methylation was significantly higher than that of the CEA level as a marker and that the combined measurement of these two indices (parallel testing) improved sensitivity. Taken together, our results suggest that the Zic1 promoter methylation rate in plasma-derived DNA is of great significance for the early screening of GC and monitoring of tumorigenesis. Zic1 promoter methylation may serve as a novel non-invasive plasma biomarker for the early detection of GC and for risk assessment in high-risk populations. The combined measurement of the Zic1 promoter methylation rate and CEA level (parallel testing) may enhance the current guidelines for the early diagnosis of GC.

Promoter Hypermethylation of BCL6B Gene is a Potential Plasma DNA Biomarker for Gastric Cancer.

Epigenetic Inactivation of Bcl6b, A Novel Functional Tumour Suppressor for Gastric Cancer, is Associated with Poor Survival

The Survival Decrease in Gastric Cancer is Associated with the Methylation of B-cell CLL/lymphoma 6 Member B Promoter

Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast and Gastric Cancer Patients

Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation is a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions.

Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis.

Methylomics Analysis Identifies a Putative STAT3 Target, SPG20, As a Noninvasive Epigenetic Biomarker for Early Detection of Gastric Cancer

Abstract P3-01-02: Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast Cancer Patients

The Biological Significance of Detecting DNA Promoter Hypermethylation by Exfoliated Cells of Gastric Juice in Gastric Cancer

Diagnostic Accuracy Of Dna Methylation In Detection Of Gastric Cancer: A Meta-Analysis

High BCL6 Expression Predicts Better Prognosis, Independent of BCL6 Translocation Status, Translocation Partner, or BCL6-deregulating Mutations, in Gastric Lymphoma.

Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.

Klotho is Silenced Through Promoter Hypermethylation in Gastric Cancer

Annexin A6 is down-regulated through promoter methylation in gastric cancer.

CHFR Promoter Hypermethylation is Associated with Gastric Cancer and Plays a Protective Role in Gastric Cancer Process

Potential Diagnostic and Prognostic Values of Detecting Promoter Hypermethylation in the Serum of Patients with Gastric Cancer

Zic1 Promoter Hypermethylation in Plasma DNA Is a Potential Biomarker for Gastric Cancer and Intraepithelial Neoplasia

Plasma cell-free DNA methylome-based liquid biopsy for accurate gastric cancer detection

Genome-Scale Methylation Analysis of Circulating Cell-Free DNA in Gastric Cancer Patients

Genome-wide DNA methylation profiling reveals a novel hypermethylated biomarker PRKCB in gastric cancer

Detection of aberrant hypermethylated spastic paraplegia-20 as a potential biomarker and prognostic factor in gastric cancer